Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “MYC Gene Rearrangement”

44 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 44 results

Large-scale testing (Phase 3)Temporarily pausedNCT04799275
What this trial is testing

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

Who this might be right for
Ann Arbor Stage III Diffuse Large B-Cell LymphomaAnn Arbor Stage IIX (Bulky) Diffuse Large B-Cell LymphomaAnn Arbor Stage IV Diffuse Large B-Cell Lymphoma+18 more
National Cancer Institute (NCI) 422
Testing effectiveness (Phase 2)Active Not RecruitingNCT03749018
What this trial is testing

Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

Who this might be right for
Aggressive Non-Hodgkin LymphomaAnn Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell LymphomaAnn Arbor Stage II B-Cell Non-Hodgkin Lymphoma+11 more
David Bond, MD 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT04479267
What this trial is testing

Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma

Who this might be right for
Diffuse Large B-Cell LymphomaHigh Grade B-Cell Lymphoma w/MYC & BCL2 or BCL6 RearrangementsHigh Grade B-Cell Lymphoma w/MYC, BCL2 & BCL6 Rearrangements+2 more
Barbara Ann Karmanos Cancer Institute 8
Testing effectiveness (Phase 2)Looking for participantsNCT06649812
What this trial is testing

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

Who this might be right for
High Grade B-Cell Lymphoma With MYC and BCL6 RearrangementsRecurrent Diffuse Large B-Cell LymphomaRecurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type+12 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Looking for participantsNCT03136146
What this trial is testing

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

Who this might be right for
Recurrent Acute Lymphoblastic LeukemiaRecurrent Adult Lymphoblastic LymphomaRecurrent Burkitt Leukemia+8 more
M.D. Anderson Cancer Center 42
Not applicableLooking for participantsNCT06588205
What this trial is testing

Exploring the Clinical Impact of MYC Aberrations and Their Relationship With Microenvironment in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma

Who this might be right for
Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaHigh Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
Fondazione Italiana Linfomi - ETS 200
Testing effectiveness (Phase 2)Looking for participantsNCT06905509
What this trial is testing

Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

Who this might be right for
Recurrent Diffuse Large B-Cell LymphomaRecurrent Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements+11 more
Joseph Tuscano
Testing effectiveness (Phase 2)Looking for participantsNCT06536049
What this trial is testing

Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Who this might be right for
Recurrent Diffuse Large B-Cell LymphomaRecurrent Grade 3b Follicular LymphomaRecurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements+11 more
Yazeed Sawalha 38
Early research (Phase 1)Ended earlyNCT02706405
What this trial is testing

JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Who this might be right for
Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Diffuse Large B-Cell LymphomaRecurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma+3 more
Fred Hutchinson Cancer Center 30
Early research (Phase 1)Ended earlyNCT03103971
What this trial is testing

HuJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia

Who this might be right for
Recurrent Adult Acute Lymphoblastic LeukemiaRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Diffuse Large B-Cell Lymphoma+14 more
Fred Hutchinson Cancer Center 55
Testing effectiveness (Phase 2)Looking for participantsNCT05890352
What this trial is testing

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

Who this might be right for
Grade 3b Follicular LymphomaHigh Grade B-Cell LymphomaHigh Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements+3 more
SWOG Cancer Research Network 227
Testing effectiveness (Phase 2)Looking for participantsNCT06806033
What this trial is testing

Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Who this might be right for
B-Cell Non-Hodgkins Lymphoma
Hoffmann-La Roche 100
Early research (Phase 1)Active Not RecruitingNCT04323956
What this trial is testing

Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma

Who this might be right for
Ann Arbor Stage II Diffuse Large B-Cell LymphomaAnn Arbor Stage II Follicular LymphomaAnn Arbor Stage II Marginal Zone Lymphoma+11 more
Mayo Clinic 50
Testing effectiveness (Phase 2)Active Not RecruitingNCT03793140
What this trial is testing

CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations

Who this might be right for
LymphomaLeukemia
Memorial Sloan Kettering Cancer Center 24
Large-scale testing (Phase 3)UnknownNCT05097443
What this trial is testing

Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma

Who this might be right for
High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 RearrangementsHigh Grade B-Cell Lymphoma, Not Otherwise SpecifiedDiffuse Large B-cell Lymphoma+2 more
Shandong Provincial Hospital 130
Testing effectiveness (Phase 2)Active Not RecruitingNCT05202782
What this trial is testing

Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma

Who this might be right for
Diffuse Large B-Cell Lymphoma Associated With Chronic InflammationEBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedHigh Grade B-Cell Lymphoma, Not Otherwise Specified+16 more
Northwestern University
Large-scale testing (Phase 3)UnknownNCT05164770
What this trial is testing

Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma

Who this might be right for
High Grade B-Cell Lymphoma, Not Otherwise SpecifiedHigh Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 RearrangementsDiffuse Large B Cell Lymphoma+2 more
Shandong Provincial Hospital 160
Testing effectiveness (Phase 2)Looking for participantsNCT06834373
What this trial is testing

Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy

Who this might be right for
Large B-Cell Lymphoma With IRF4 RearrangementRecurrent Aggressive B-Cell Non-Hodgkin LymphomaRecurrent ALK-Positive Large B-Cell Lymphoma+28 more
Mayo Clinic 41
Testing effectiveness (Phase 2)Active Not RecruitingNCT03620578
What this trial is testing

DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBL

Who this might be right for
Non Hodgkin LymphomaLymphoma, B-CellHigh-grade B-cell Lymphoma+2 more
Stichting Hemato-Oncologie voor Volwassenen Nederland 97
Testing effectiveness (Phase 2)Study completedNCT02199184
What this trial is testing

Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia

Who this might be right for
AIDS-Related Burkitt LymphomaAtypical Burkitt/Burkitt-Like LymphomaHigh Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements+5 more
M.D. Anderson Cancer Center 14
Load More Results
120
25
24